News

Published on 22 Jul 2022 on Zacks via Yahoo Finance

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off


Article preview image

This week, J&J JNJ set in motion the second-quarter earnings season for the drug and biotech sector with an earnings and sales beat. Novartis NVS reported mixed results. GSK plc GSK completed the separation of its Consumer Healthcare (CHC) segment into a new company, Haleon. Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant.

Recap of the Week’s Most Important Stories

J&J Beats on Q2 Earnings & Sales, Lowers View: J&J reported better-than-expected second-quarter results as it beat estimates for both earnings and sales. Its Pharmaceuticals unit continued to do well. Its COVID-19 vaccine sales improved in the second quarter after a lower-than-expected contribution in the first quarter. Sales in the MedTech segment continued to improve. However, sales were partly hurt by COVID-related restrictions in countries like China and labor and supply constraints.

NASDAQ.SNY price evolution
NYSE.NVS price evolution
SIX.NOVN price evolution
PAR.SAN price evolution
PAR.MRK price evolution
LSE.AZN price evolution
LSE.APH price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Look beyond the Magnificent 7 to the GRANOLAS - Goldman

Investors looking to diversify from U.S. large-cap stocks should look to the top performers in...

Seeking Alpha 24 Mar 2024

1 Magnificent Dividend Stock to Buy and Hold

There are plenty of dividend stocks on the market. However, some raise their payouts irregularly,...

Motley Fool via Yahoo Finance 24 Mar 2024

MorphoSys stock gains after gaining U.S. antitrust approval for sale to Novartis

MorphoSys rose 1% as its $2.7 billion sale to Novartis cleared U.S. antitrust regulators. The HSR...

Seeking Alpha 22 Mar 2024

BioNTech names new chief commercial officer ahead of launches

BioNTech names new chief commercial officer ahead of launches

Investing.com 20 Mar 2024

Investing $10,000 in Each of These 3 Vanguard ETFs Could Generate $1,164 per Year in Passive Income

What's Warren Buffett's favorite fund manager? It's almost certainly Vanguard. He has bought only...

Motley Fool via Yahoo Finance 17 Mar 2024

Novartis AG (VTX:NOVN) most popular amongst individual investors who own 54% of the shares,...

Key Insights Novartis' significant individual investors ownership suggests that the key decisions...

Simply Wall St. via Yahoo Finance 17 Mar 2024

MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript

MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript March 14, 2024 MorphoSys AG isn't one ...

Insider Monkey via Yahoo Finance 15 Mar 2024

12 Most Profitable Biotech Stocks To Invest In

In this piece, we will take a look at the 12 most profitable biotech stocks to invest in. If you ...

Insider Monkey via Yahoo Finance 14 Mar 2024

Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock

Novartis (NVS) has been one of the most searched-for stocks on Zacks.com lately. So, you might wa...

Zacks via Yahoo Finance 14 Mar 2024

Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come

(Bloomberg) -- A rash of dealmaking helped reverse the declining fortunes of biotech stocks over ...

Bloomberg via Yahoo Finance 14 Mar 2024